Skip to main content
18 February 2019
Last updated:
Monday 18 February 2019

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
    • News
    • Appointments
    • Events
  • About MedNous
  • Research Directory
  • Contact Us

News

Novo sees currency-adjusted sales growth

Thursday 1 November 2018
Country

Denmark

Novo Nordisk A/S expects sales and operating profit to increase in 2018 on a currency-adjusted basis as it takes steps to reduce its workforce and diversify its portfolio. The Danish producer of diabetes products is expanding into other biologic products as well as new delivery technologies for insulin.

Read more

Glimpse of recovery at Sanofi

Thursday 1 November 2018
Country

France

Sanofi reported higher net earnings per share in the third quarter and is forecasting a rise for the year as a whole. But a continued decline in US insulin sales translated into a lower gross profit margin for the quarter and the first nine months of 2018. 

Read more

GSK gives earnings guidance

Wednesday 31 October 2018
Country

United Kingdom

GlaxoSmithKline Plc has issued improved guidance for adjusted earnings per share for 2018 following an increase in sales at constant exchange rates for the third quarter and first nine months, and a better operating margin. In a teleconference with journalists on 31 October, Emma Walmsley, the chief executive, highlighted sales of the company’s shingles’ vaccine Shingrix, the HIV medicines Triumeq and Tivicay, and new respiratory products.

Read more

Themis gives terms of share offering

Monday 29 October 2018
Country

Austria

Austria-based Themis Bioscience GmbH may raise up to €55.3 million in an initial public offering on Euronext Amsterdam and share placements in the US and elsewhere to finance the clinical development of its lead vaccine for Chikungunya, a mosquito-borne viral infection.

Read more

Galecto raises €79 million in Series C round

Friday 26 October 2018
Country

Denmark

Denmark-based Galecto Biotech AB has raised €79 million in a Series C financing round to support a Phase 2/3 trial of its lead product for the treatment of idiopathic pulmonary fibrosis, a chronic disease characterised by a progressive decline in lung function.

Read more

Schizophrenia drug fails at Phase 3

Friday 26 October 2018
Country

Denmark

A prospective treatment for patients with schizophrenia, who have not responded to other drugs, failed to show statistical superiority in a Phase 3 trial compared with conventional therapy, H. Lundbeck A/S announced on 25 October.

Read more

AbbVie to take control of cystic fibrosis programme

Thursday 25 October 2018
Country

United States

AbbVie Inc is to take full control of a joint cystic fibrosis (CF) research and development programme with Galapagos NV with the goal of bringing a triple combination CF therapy to the market. Currently in early clinical development, the programme consists of potentiator and corrector drug molecules that are intended to increase the activity of mutated copies of the cystic fibrosis transmembrane conductance regulator protein that causes the disease.

Read more

Microbiome deal between Enterome and Takeda

Wednesday 24 October 2018
Country

France

France-based Enterome SA has out-licensed its lead microbiome-directed product for the treatment of Crohn’s disease to Takeda Pharmaceutical Company Ltd for the treatment of Crohn’s disease, generating an upfront payment of $50 million, a future equity investment and potential milestone payments of $640 million.

Read more

Filgotinib trial results published in The Lancet

Tuesday 23 October 2018
Country

United States

Positive data from two Phase 2 studies of filgotinib, a Janus kinase 1 inhibitor being developed for several inflammatory conditions, were published online on 22 October 2018 in The Lancet, Gilead Sciences Inc and Galapagos NV announced.

Read more

First vaccine for prevention of dengue

Sunday 21 October 2018

The European Medicines Agency has recommended the approval of Dengvaxia (dengue tetravalent vaccine) for the prevention of dengue, the most common mosquito-borne viral disease affecting people worldwide. The vaccine is for the prevention of dengue caused by the virus serotypes 1,2,3 and 4 in people between the ages of nine and 45 and who have already had a prior infection.

Read more

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Current page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • …
  • Next page next ›
  • Last page last »

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Donato Spota to become CFO at Hansa Biopharma
Thursday February 7 2019
Georgia Gavriilidou joins Sidley Austin
Thursday February 7 2019
Alan Knox becomes CEO at Primex
Thursday February 7 2019
Kiadis appoints Robert Friesen as CSO
Thursday February 7 2019
Samantha Paston to head research at Scancell
Thursday February 7 2019

© 2018 Evernow Publishing Ltd. Powered by Drupal.